A Phase 2 interventional study of Q10 in Non-Alcoholic Fatty Liver Disease, sponsored by Attikon Hospital. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-12.
Sponsored by Attikon Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece — 3 open to participants now, 6 under way, 2 of them phase 3. Non-alcoholic Fatty Liver Disease · Greece.
Among the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 in phase 2, and was the 20th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →3 of the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece are open now. Recruiting first, the newest first:
Akero Therapeutics, Inc · Sites in Greece, United States, Argentina and 20 more countries
Ages 18–80
Newcastle University · Sites in Greece, Belgium, Finland and 9 more countries
Ages 18–100
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 100 across the 20 interventional studies, 264 across the 4 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 24 have an industry lead sponsor. The 10 most frequent:
Attikon Hospital is the lead sponsor of 86 studies on the registry; 17 are open to participants now.
Attikon Hospital has 1 study filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Non-alcoholic Fatty Liver Disease with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06523530Aristotle University Of ThessalonikiEffect of a GnRH Analog on Hepatic Steatosis | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients with NAFLD
Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients with NAFLD. In this trial patients with NAFLD will receive 240mg Q10 or placebo. At baseline and at 6 months, will be measured: a) Perfused boundary region (PBR) of the sublingual vessels using the SideviewDarkfieldimaging technique (Microscan, Glycocheck), b) pulse wave velocity (PWV-Complior, ALAM), c) flow-mediated dilation (FMD) of the brachial artery, d) left ventricular (LV) global longitudinal strain (GLS), and e) controlled attenuation parameter (CAP)for the quantification of liver steatosis by liver elastography (Fibroscan, Echosens).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NAFLD AND one of below :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Q10
Drug: Q10
240mg of Q10 orally, every day
The effect of Q10 on Left Ventricular Myocardial Function
The effect of Q10 on Left Ventricular Global Longitudinal Strain after six month administration of Q10
Time frame: Six months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Aug 2023, 4 months after the start.
Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's planned 4 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Coenzyme Q10
Non-alcoholic Fatty Liver Disease →
Attikon Hospital